Corvus Pharmaceuticals Inc (CRVS)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

863 MITTEN ROAD BURLINGAME, CA 94010

Corvus Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. Corvus Pharmaceuticals operates in the United States.

Data as of 2020-11-22
Market Cap111.967 Million Shares Outstanding28.062 Million Avg 30-day Volume177.831 Thousand
P/E Ratio-2.6 Dividend Yield EPS-1.51
Price/Sales Price cash flow ratio Price free cash flow ratio-3.2
Book Value1.51 Price to Tangible Book2.64 Alpha-0.01
Short Interest Ratio % Short Interest to Float R-squared0.123276
BETA2.0119 52-week High/Low6.88 / 1.01 Stddev0.242886
View SEC Filings from CRVS instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 2 2 0.0% 2 (0.13%) 2 (0.13%) 0.0%
Funds Holding: 39 39 0.0% 13 (0.85%) 17 (1.1%) -23.53%
13F shares: 17.217 Million 20.441 Million -15.77% 13.986 Million 15.843 Million -11.72%
% Ownership 61.4118 72.912 -15.77% 49.8867 56.5116 -11.72%
New Positions: 7 2 250.0% 2 1 100.0%
Increased Positions 11 11 0.0% 1 6 -83.33%
Closed Positions 7 7 0.0% 6 2 200.0%
Reduced Positions 12 9 33.33% 6 4 50.0%
Total Calls 50.024 Thousand 1 5002300.0%
Total Puts 7.8 Thousand 0
PUT/CALL Ratio 0.16 0.0
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding CRVS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CRVS BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MITCHELL EDITH P.

  • Director
0 2020-09-10 2

NOVO HOLDINGS A/S

  • 10% Owner
1,389,498 2020-07-07 2

GOULD TERRY P

  • Director
  • 10% Owner
3,275,616 2020-06-09 2

THOMPSON PETER A.

  • Director
  • 10% Owner
6,767,584 2020-06-09 2

KROGNES STEVE E.

  • Director
0 2020-06-09 2

MORRISON SCOTT W

  • Director
0 2020-06-09 2

ADAMS STREET PARTNERS LLC

  • 10% Owner
3,275,616 2020-06-09 2

CLARK IAN T

  • Director
0 2020-06-09 2

GRAIS LINDA S

  • Director
0 2020-06-09 2

JONES WILLIAM BENTON SEE REMARKS

  • Officer
0 2019-12-12 1

VERNER ERIK J. VP, CHEMISTRY RESEARCH

  • Officer
0 2019-12-12 1

MILLER RICHARD A MD PRESIDENT AND CEO

  • Officer
  • Director
0 2019-12-12 1

LEA LEIV CHIEF FINANCIAL OFFICER

  • Officer
0 2019-12-12 1

HUNT DANIEL W. SVP, CHIEF BUSINESS OFFICER

  • Officer
0 2019-12-12 1

BUGGY JOSEPH J EVP, DISCOVERY RESEARCH

  • Officer
0 2019-12-12 1

MOBASHER MEHRDAD VP, CHIEF MEDICAL OFFICER

  • Officer
0 2019-12-12 1

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP V LLC

  • Director
  • 10% Owner
6,767,584 2019-08-06 0

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP V LLC

ISALY SAMUEL D

  • Director
  • 10% Owner
5,379,349 2016-06-23 0

COLOMA JASON V SVP, CHIEF BUSINESS OFFICER

  • Officer
0 2016-06-08 0

ORBIMED ADVISORS LLC

  • Director
  • 10% Owner
5,258,450 2016-03-29 0

MOLDT PETER

  • Director
0 2016-03-22 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments